Rebecca Johnson

Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma

James R. Patrinely, Rebecca Johnson, Aleigha Lawless et al. · JAMA Oncology · 2021 · 250 citations · Full text

Life Sciences, Immunology, Oncology +17

Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study

Xue Bai, Shaheen Ahmed, Charlotte Grieco et al. · EClinicalMedicine · 2023 · 27 citations · Full text

Medicine, Oncology, Surgery +17

Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy

Prachi Bhave, Angela Hong, Serigne Lo et al. · Journal for ImmunoTherapy of Cancer · 2023 · 19 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort study

Xue Bai, Aleigha Lawless, Juliane A. Czapla et al. · JAAD International · 2024 · 16 citations · Full text

Medicine, Clinical Sciences, Oncology +16